BTIG Downgrades Orchestra BioMed Inc. (OBIO) to Neutral

BTIG analyst Marie Thibault downgraded Orchestra BioMed Inc. (NASDAQ: OBIO) from Buy to Neutral.

The analyst comments "We are downgrading our recommendation on Orchestra BioMed from Buy to Neutral. Among the factors pushing us to the sidelines: the company's recent dilutive equity financing while maintaining its pace of spending; strategic funding that reduces future profitability; slipped timelines over the past several quarters on key catalysts; and a lack of certainty around positive near-term developments that could help shares. We previously expected a resolution on the Terumo Corporation (4543-TKS, Not Rated) partnership in Q2, that prior protocol changes for the BACKBEAT trial would be sufficient to boost enrollment, and that the company would prioritize less dilutive sources of funding. We have since seen the Terumo arbitration timeline slide to late Q3, another protocol change for the BACKBEAT trial and another shift in timing from 1H26 to mid-2026, and a financing that did include non-dilutive strategic investment but also an equity offering resulting in >30% dilution. We do expect the Terumo resolution by late September but do not know if this will end with a continued partnership and milestone payments or if OBIO will need to find a new commercial partner for the Virtue SAB program. We also expect that OBIO will need to find future sources of funding in the 2027 timeframe and that hitting its timelines for the BACKBEAT trial and FDA approval is becoming increasingly crucial. Once commercial, this month's strategic investments from Medtronic (MDT, Neutral, Zimmerman), and Ligand Pharmaceuticals (LGND, Not Rated) may make OBIO's future opex profile less appealing. We remain believers in OBIO's science but are less confident in the company's ability to hit R&D timelines and secure and maintain commercial partnerships at a reasonable pace of spending. We downgrade to Neutral and remove our price target."

For an analyst ratings summary and ratings history on Orchestra BioMed Inc. click here. For more ratings news on Orchestra BioMed Inc. click here.

Shares of Orchestra BioMed Inc. closed at $2.55 yesterday.

You May Also Be Interested In

• Axis Capital Limited Downgrades Godrej Consumer Products Ltd. (GCPL:IN) to Add (2)
• Berenberg Starts Raspberry PI Holdings PLC (RPI:LN) at Hold
• Berenberg Upgrades Clariant AG (CLN:SW) (CLZNY) to Buy